Constellation raises $100M venture round

Cancer epigenetics company Constellation Pharmaceuticals Inc. (Cambridge, Mass.) raised $100 million in an untranched venture round from new investors Cormorant Asset Management, Deerfield Management, Fidelity Management, Hillhouse Capital, NS Investment, OrbiMed and Sirona Capital. Existing investors The Column Group, Third Rock Ventures, Venrock, SR One, University of California Investment Office, Topspin Partners and Casdin Capital also participated.

Constellation's lead candidates are CPI-1205, an enhancer of zeste homolog 2 (EZH2) inhibitor, and CPI-0610, a BET bromodomain inhibitor. ...